- Home
- KAPA vs MBRX Comparison
KAPA vs MBRX Comparison
Compare KAPA & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAPA
- MBRX
- Stock Information
- Founded
- KAPA 2013
- MBRX 2015
- Country
- KAPA United States
- MBRX United States
- Employees
- KAPA N/A
- MBRX N/A
- Industry
- KAPA
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- KAPA
- MBRX Health Care
- Exchange
- KAPA NYSE
- MBRX Nasdaq
- Market Cap
- KAPA 10.8M
- MBRX 12.9M
- IPO Year
- KAPA 2024
- MBRX 2016
- Fundamental
- Price
- KAPA $1.10
- MBRX $0.82
- Analyst Decision
- KAPA Strong Buy
- MBRX Strong Buy
- Analyst Count
- KAPA 3
- MBRX 3
- Target Price
- KAPA $8.33
- MBRX $5.33
- AVG Volume (30 Days)
- KAPA 13.5M
- MBRX 13.1M
- Earning Date
- KAPA 08-23-2025
- MBRX 08-13-2025
- Dividend Yield
- KAPA N/A
- MBRX N/A
- EPS Growth
- KAPA N/A
- MBRX N/A
- EPS
- KAPA N/A
- MBRX N/A
- Revenue
- KAPA N/A
- MBRX N/A
- Revenue This Year
- KAPA N/A
- MBRX N/A
- Revenue Next Year
- KAPA N/A
- MBRX N/A
- P/E Ratio
- KAPA N/A
- MBRX N/A
- Revenue Growth
- KAPA N/A
- MBRX N/A
- 52 Week Low
- KAPA $0.40
- MBRX $0.25
- 52 Week High
- KAPA $4.00
- MBRX $4.71
- Technical
- Relative Strength Index (RSI)
- KAPA N/A
- MBRX 71.04
- Support Level
- KAPA N/A
- MBRX $0.50
- Resistance Level
- KAPA N/A
- MBRX $0.73
- Average True Range (ATR)
- KAPA 0.00
- MBRX 0.10
- MACD
- KAPA 0.00
- MBRX 0.07
- Stochastic Oscillator
- KAPA 0.00
- MBRX 94.61
About KAPA KAIROS PHARMA LTD
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.